| Technical Name | Small-molecule drugs for diabetes reversal | ||
|---|---|---|---|
| Project Operator | Academia Sinica | ||
| Project Host | 楊文欽 | ||
| Summary | Type 2 diabetes (T2D) is now still an incurable disease. This invention is to apply PX inhibitors to treat and reverse T2D. These inhibitors, small-molecule drugs, are first-in-class drugs for T2D due to its novel anti-diabetic mode of action. |
||
| Scientific Breakthrough | Type 2 diabetes (T2D) is now still an incurable disease. PX is a novel target for diabetes and its knockout fully reverses T2D and prolong life span in diabetic mice. This invention relates to PX-based inhibitors, which can reduce PX activity. Moreover, they can be used as small-molecule drugs for treating and reversing T2D. These drugs exert anti-diabetic action via improvement of β-cell functions and survival. |
||
| Industrial Applicability | This invention is to develop PX-based inhibitors for type 2 diabetes (T2D). Since PX is a novel target of T2D, such inhibitors are first-in-class drugs. This invention not only helps pharmaceutical company upgrade their research capacity but also reduce the burden of T2D in patients. besides, its market is valued 12.5 billion US dollars. |
||
| Keyword | Diabetes Beta cells Reversal Treatment PX inhibitors First-in-class drug for diabetes Small molecules Therapeutics Longevity Cure | ||
- zong770115@gmail.com
other people also saw
